<DOC>
	<DOCNO>NCT00419536</DOCNO>
	<brief_summary>This 2-arm study design determine maximum tolerate dose LBH589 single agent combination docetaxel prednisone 5 mg twice daily ( second arm ) characterize safety , tolerability , biologic activity pharmacokinetic profile .</brief_summary>
	<brief_title>Safety LBH589 Alone Combination With Intravenous Docetaxel Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients hormone refractory prostate cancer Patients must metastatic disease least 1 measurable soft tissue lesion assess CT MRI and/or detectable lesion ( ) bone scintigraphy scan . Patients elevate PSA level eligible entry . Patients must meet laboratory inclusion criterion define protocol Patients must able provide write informed consent Patients prior concurrent brain metastasis Impaired cardiac , gastrointestinal , kidney liver function Use therapeutic androgen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>LBH</keyword>
	<keyword>LBH589</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
</DOC>